BOSTON, MA, UNITED STATES - Oct 28, 2019 - BOSTON, MA - Convening at the Colonnade Hotel, attendees of the 4th FierceBiotechDrug Development Forum will gain executive-level insights into the end-to-end drug development process, with one track focusing on early R&D, clinical development, through product commercialization. The second track explores financing strategies and approaches to supplementing pipeline growth through M&A, licensing, and joint ventures, discussing best practices for mitigating risks and maximizing the potential of these transactions.

Most new products today have either been developed through internal R&D or sourced through M&A and licensing deals. It requires the right expertise to design and execute trials, generate evidence that communicates the value of a product to payers and health systems, and build out a commercial function in support of a product. Given the significant risks associated with the development of new therapeutics and the sizeable investment required upfront, many companies look to external sources of innovation and early partnership opportunities to supplement organic pipeline growth and replace key products within their portfolios.

Over two days, the 4th FierceBiotech Drug Development Forum will showcase how leaders from biotechs and big pharma companies navigate today’s competitive landscape and highlight what it takes to ensure the successful development of a commercially viable product in the current healthcare environment. The complete agenda, faculty list, and registration information is available at www.FierceDrugDevForum.com.

Featured Sessions

Prioritize, Consolidate, and Refine R&D Investment Through Strategic Portfolio/Pipeline Planning to Deliver the Greatest Overall Value to Your Company and Shareholders

Sandy Macrae,CEO,SANGAMO THERAPEUTICS

Joanna Wolkowski,Vice President, Portfolio and Decision Analysis,PFIZER

Pearl S. Huang, Ph.D.,President and CEO,CYGNAL THERAPEUTICS

Frederic Chereau,CEO,LOGICBIO THERAPEUTICS

Build Vs. Buy: Key Considerations for Deciding Whether to Commercialize on Your Own or Find a Strategic Partner

Michael R Williams,Chief Business Officer,ABREOS BIOSCIENCES

Molly Harper,Senior Vice President and Global Franchise General Manager,AKCEA THERAPEUTICS

Rich Daly,Chief Operating Officer,BEYONDSPRING PHARMACEUTICALS

Buy-Side BD&L: Insights Into Process and Decision-Making at Big Pharma/Big Biotech

Kleem Chaudhary, Ph.D.,Head BD&L,BIOGEN

Lizabeth Leveille,Associate Vice President and Head, Boston Innovation Hub, BD&L,MERCK

Lance Ostrom,Head, Boston Innovation Hub, Roche Partnering,ROCHE

Brendan Downey,Director, Center for External Innovation,TAKEDA PHARMACEUTICALS

New Indications in the Approval of Medicines

David Weinreich, M.D.,Senior Vice President, Head, Global Clinical

Development, REGENERON

Robert Paul, M.D., Ph.D.,Chief Medical Officer, ALECTOR

Explore How AI and Machine Learning Can Be the Backbone to Building a Hypothesis for Drug Discovery

Roman Yelensky, Ph.D.,Executive Vice President and Chief Technology Officer,GRITSTONE ONCOLOGY

Ron Alfa, Ph.D., M.D.,Vice President of Translational Research,RECURSION PHARMACEUTICALS

Dr. Josep Bassaganya-Riera,Chairman and CEO, LANDOS BIOPHARMA

Pat Walters, Ph.D.,Senior Vice President, Computation,RELAY THERAPEUTICS

Gregory Ryslik, Ph.D., FCAS, MAAA,Chief Data Officer,CELSIUS THERAPEUTICS

Key Questions Small Companies Should Ask When Evaluating Potential Partners

Robert Bagdorf, M.D., MBA,Group Lead, Search and Evaluation, Worldwide Business Development,PFIZER

Thomas Neenan,CEO,ABFERO PHARMACEUTICALS

Albert Hsia, Ph.D.,Executive Director, Business Development,MERCK & CO.

Gil Labrucherie,Senior Vice President and Chief Financial Officer,NEKTAR THERAPEUTICS

CONTACT

For information on exhibition and sponsorship opportunities, please contact Shauna Greig at 212-400-6228 or sgreig@questex.com.

RELATED LINK

www.FierceDrugDevForum.com